Could a new drug help keep myasthenia gravis symptoms at bay?

NCT ID NCT07673744

Recruiting now Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether ublituximab, given as an infusion, can help adults with myasthenia gravis maintain symptom control after initial treatment with efgartigimod. Participants will receive either ublituximab or a placebo, and researchers will track how long it takes for symptoms to worsen. The goal is to see if ublituximab can delay or prevent flare-ups in this autoimmune disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab (BRIUMVI)
What this could lead to: If successful, this could provide a new maintenance option to help people with myasthenia gravis stay stable longer and delay symptom worsening.
What could go wrong: This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

TG Therapeutics Investigational Trial Site
RECRUITING

Colorado Springs, Colorado, 80919, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Clearwater, Florida, 33761, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.